SBI Securities Co. Ltd. Sells 64,433 Shares of Gyre Therapeutics, Inc. $GYRE

SBI Securities Co. Ltd. reduced its holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 27.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 167,866 shares of the company’s stock after selling 64,433 shares during the quarter. SBI Securities Co. Ltd. owned approximately 0.17% of Gyre Therapeutics worth $1,252,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of GYRE. State of Alaska Department of Revenue acquired a new stake in Gyre Therapeutics in the third quarter valued at $38,000. Bank of America Corp DE grew its position in shares of Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after buying an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares during the period. Finally, Strs Ohio raised its position in shares of Gyre Therapeutics by 58.6% during the third quarter. Strs Ohio now owns 21,100 shares of the company’s stock worth $157,000 after acquiring an additional 7,800 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Stock Up 4.9%

Shares of NASDAQ GYRE opened at $7.88 on Friday. The firm has a market cap of $759.08 million, a PE ratio of 262.75 and a beta of 1.97. The company’s fifty day simple moving average is $7.65 and its 200 day simple moving average is $7.68. Gyre Therapeutics, Inc. has a 12-month low of $6.11 and a 12-month high of $13.75.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GYRE shares. Jefferies Financial Group initiated coverage on shares of Gyre Therapeutics in a research note on Friday, October 10th. They issued a “buy” rating and a $16.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Finally, Wall Street Zen raised Gyre Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.